Our groundbreaking research is referenced by the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP) Drug Safety Journal.
The WHO publication titled “Pregnancy Exposure Registries in Low- and Middle-Income Countries (LMICs)*” sheds light on the vital role of pregnancy exposure registries in LMICs. According to the WHO publication, pregnancy registries play a pivotal role in monitoring the safety and outcomes of medications, vaccines, and other exposures during pregnancy, especially in regions where such data are scarce. The research conducted by CorEvitas’ pregnancy registry has significantly contributed to filling this critical gap in knowledge.
Findings from our pregnancy registry studies have been acknowledged in the Drug Safety Journal by the International Society of Pharmacovigilance (ISoP). The manuscript titled “The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations,” published in the journal, assesses the relative risk of obstetric, neonatal, and infant outcomes associated with the use of drugs specifically indicated for the treatment of COVID-19 compared with other drug treatment strategies. These data provide valuable insights about COVID-19 treatment during pregnancy for healthcare professionals, policymakers, and researchers.
The acknowledgement of these data in prestigious publications reaffirms the importance of pregnancy registry studies in facilitating evidence-based decision-making to improve maternal and fetal health outcomes worldwide.
For more information about CorEvitas’ pregnancy registries, click here
Read the abstract: The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations
Download the WHO publication: Pregnancy Exposure Registries in Low- and Middle-Income Countries (LMICs)*
*Landscape analysis of pregnancy exposure registries in low- and middle-income countries. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).”